SPOTLIGHT -
Dr. Altomare on Investigational Agents in ITP
Ivy P. Altomare, MD, discusses investigational agents in immune thrombocytopenia.
Read More
Dr. Altomare on the Challenges of Treating ITP
Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune thrombocytopenia.
Dr. Altomare on Treatment Options in ITP
Ivy P. Altomare, MD, discusses treatment options for patients with immune thrombocytopenia purpura.
Dr. Altomare on the Management of ITP
Ivy P. Altomare, MD, discusses the management of patients with immune thrombocytopenia purpura.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
